Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CRLBF NASDAQ:DNLI NASDAQ:IBRX NASDAQ:MLYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLBFCresco Labs$0.97-1.5%$0.92$0.43▼$1.77$483.65M1.561.36 million shs932,183 shsDNLIDenali Therapeutics$13.16-7.3%$14.57$10.57▼$33.33$2.07B1.231.93 million shs1.64 million shsIBRXImmunityBio$2.74+5.4%$2.55$1.83▼$7.48$2.46B0.38.57 million shs26.97 million shsMLYSMineralys Therapeutics$36.21-2.4%$18.38$8.24▼$39.20$2.46B-0.292.59 million shs1.68 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLBFCresco Labs-1.45%-18.43%-1.21%+105.01%-41.52%DNLIDenali Therapeutics-7.26%-15.10%-10.48%-6.07%-57.23%IBRXImmunityBio+5.38%+13.69%+7.45%-3.52%-23.46%MLYSMineralys Therapeutics-2.40%+0.78%+149.38%+162.77%+207.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLBFCresco Labs$0.97-1.5%$0.92$0.43▼$1.77$483.65M1.561.36 million shs932,183 shsDNLIDenali Therapeutics$13.16-7.3%$14.57$10.57▼$33.33$2.07B1.231.93 million shs1.64 million shsIBRXImmunityBio$2.74+5.4%$2.55$1.83▼$7.48$2.46B0.38.57 million shs26.97 million shsMLYSMineralys Therapeutics$36.21-2.4%$18.38$8.24▼$39.20$2.46B-0.292.59 million shs1.68 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLBFCresco Labs-1.45%-18.43%-1.21%+105.01%-41.52%DNLIDenali Therapeutics-7.26%-15.10%-10.48%-6.07%-57.23%IBRXImmunityBio+5.38%+13.69%+7.45%-3.52%-23.46%MLYSMineralys Therapeutics-2.40%+0.78%+149.38%+162.77%+207.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRLBFCresco Labs 3.00BuyN/AN/ADNLIDenali Therapeutics 3.12Buy$33.50154.56% UpsideIBRXImmunityBio 3.20Buy$10.75292.34% UpsideMLYSMineralys Therapeutics 2.83Moderate Buy$43.5020.13% UpsideCurrent Analyst Ratings BreakdownLatest CRLBF, MLYS, IBRX, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025MLYSMineralys TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $50.009/10/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/9/2025MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $52.009/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/8/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.009/3/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$15.00 ➝ $26.008/28/2025MLYSMineralys TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $43.008/26/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/14/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRLBFCresco Labs$724.34M0.66N/AN/A$0.79 per share1.23DNLIDenali Therapeutics$330.53M5.82N/AN/A$8.53 per share1.54IBRXImmunityBio$14.74M175.71N/AN/A($0.57) per share-4.81MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRLBFCresco Labs-$74.44M-$0.13N/AN/AN/A-6.67%-11.77%-3.22%11/14/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)Latest CRLBF, MLYS, IBRX, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78-$0.66+$0.12-$0.66N/AN/A8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/7/2025Q2 2025CRLBFCresco Labs-$0.04-$0.05-$0.01-$0.05$162.00 million$163.62 million8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRLBFCresco LabsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRLBFCresco Labs1.333.102.22DNLIDenali Therapeutics0.0110.2710.27IBRXImmunityBioN/A4.113.98MLYSMineralys TherapeuticsN/A15.1215.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRLBFCresco Labs0.05%DNLIDenali Therapeutics92.92%IBRXImmunityBio8.58%MLYSMineralys Therapeutics84.46%Insider OwnershipCompanyInsider OwnershipCRLBFCresco LabsN/ADNLIDenali Therapeutics12.50%IBRXImmunityBio76.79%MLYSMineralys Therapeutics25.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRLBFCresco Labs2,900491.02 millionN/ANot OptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableIBRXImmunityBio590945.26 million219.39 millionOptionableMLYSMineralys Therapeutics2866.30 million44.26 millionOptionableCRLBF, MLYS, IBRX, and DNLI HeadlinesRecent News About These CompaniesMineralys Therapeutics falls -4.9%September 15 at 7:18 PM | msn.comMineralys Therapeutics (NASDAQ:MLYS) Sees Unusually-High Trading Volume Following Analyst UpgradeSeptember 13 at 10:14 AM | marketbeat.comWells Fargo & Company Increases Mineralys Therapeutics (NASDAQ:MLYS) Price Target to $50.00September 13 at 8:51 AM | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Sees Strong Trading Volume on Analyst UpgradeSeptember 13 at 2:19 AM | americanbankingnews.comMineralys Therapeutics (NASDAQ:MLYS) Price Target Raised to $50.00 at Wells Fargo & CompanySeptember 12, 2025 | americanbankingnews.comMineralys Therapeutics price target raised to $50 from $26 at Wells FargoSeptember 11, 2025 | msn.comThe Goldman Sachs Group Increases Mineralys Therapeutics (NASDAQ:MLYS) Price Target to $52.00September 11, 2025 | marketbeat.comJefferies Reaffirms Their Hold Rating on Mineralys Therapeutics, Inc. (MLYS)September 10, 2025 | theglobeandmail.comMineralys Therapeutics (NASDAQ:MLYS) Director Srinivas Akkaraju Acquires 588,235 Shares of StockSeptember 10, 2025 | marketbeat.comRa Capital Management, L.P. Acquires 1,176,470 Shares of Mineralys Therapeutics (NASDAQ:MLYS) StockSeptember 10, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Reaches New 52-Week High - Here's WhySeptember 10, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Mineralys Therapeutics (NASDAQ:MLYS)September 10, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Given New $52.00 Price Target at The Goldman Sachs GroupSeptember 10, 2025 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Mineralys Therapeutics (NASDAQ:MLYS)September 10, 2025 | americanbankingnews.comWhat Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comPolar Asset Management Partners Inc. Sells 78,970 Shares of Mineralys Therapeutics, Inc. $MLYSSeptember 9, 2025 | marketbeat.comMineralys Therapeutics (NASDAQ:MLYS) Director Buys $14,999,992.50 in StockSeptember 9, 2025 | insidertrades.comParkman Healthcare Partners LLC Buys Shares of 293,928 Mineralys Therapeutics, Inc. $MLYSSeptember 8, 2025 | marketbeat.comBuy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial PositionSeptember 8, 2025 | tipranks.comCinctive Capital Management LP Invests $226,000 in Mineralys Therapeutics, Inc. $MLYSSeptember 8, 2025 | marketbeat.comBuy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market PositionSeptember 8, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRLBF, MLYS, IBRX, and DNLI Company DescriptionsCresco Labs OTCMKTS:CRLBF$0.97 -0.01 (-1.45%) As of 09/15/2025 03:59 PM EasternCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.Denali Therapeutics NASDAQ:DNLI$13.16 -1.03 (-7.26%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$13.12 -0.04 (-0.27%) As of 06:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.ImmunityBio NASDAQ:IBRX$2.74 +0.14 (+5.38%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$2.74 -0.01 (-0.18%) As of 06:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Mineralys Therapeutics NASDAQ:MLYS$36.21 -0.89 (-2.40%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$35.50 -0.71 (-1.96%) As of 06:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
